Back to search results
NCT07644806

Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction

Not Yet Recruiting
NAAges 18–85InterventionalTreatment
Old Dominion University
~40 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Extra-virgin olive oil

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in 24-hour dietary recall monounsaturated fatty acids (MUFA)
Measured over At baseline, and 12-week
+1 more outcome measured

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)

Explore related trials

Heart failure with reduced ejection fraction

NCT07644806

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Strelitz Diabetes Center (Williams Hall)

    Norfolk, Virginiastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Salvatore Carbone, PhD, RDN · PRINCIPAL_INVESTIGATOR · Macon & Joan Brock Virginia Health Sciences at Old Dominion University

Who to contact

Salvatore Carbone, PhD, RDN
[email protected]
757-446-7149
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %.
Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session).
Able and willing to comply with study procedures and provide informed consent.

Exclusion

Co-morbidity expected to limit survival (e.g., terminal illness).
End-stage renal disease.
Unstable fluid overload.
Current pregnancy (self-disclose).
Habitual use of EVOO greater than 4 tablespoons per day.
Known allergy or sensitivity to olive oil or its components.
Unwillingness or inability to incorporate EVOO or dietary recommendations.

What this trial measures

  • Change in 24-hour dietary recall monounsaturated fatty acids (MUFA)At baseline, and 12-week

    Measured with validated 24-hour dietary recall (non-self administered)

  • Change in dietary compliance (plasma monounsaturated fatty acids)At baseline and 12-week

    Measured by changes in biomarkers of monounsaturated fatty acids (MUFA) consumption. Plasma concentrations of MUFA reflect the consumption of a diet rich in MUFA fatty acids, such as oleic acid found in extra-virgin olive oil, making them reliable biomarkers of dietary adherence.